Cash Flow Xbrane Biopharma AB Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-43.00
-253.00
-322.00
-168.00
-183.00
-218.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-249.00
42.00
-119.00
-30.00
-38.00
-18.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-250.00
-133.00
-406.00
-193.00
-219.00
-238.00
Cash Flow from Investing Activities
-37.00
-52.00
-16.00
-60.00
-77.00
-3.00
Cash Flow from Financing Activities
255.00
243.00
298.00
148.00
349.00
322.00
Net Cash Inflow / Outflow
-38.00
58.00
-129.00
-101.00
53.00
78.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
-6.00
0.00
-4.00
4.00
1.00
-1.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in SEK Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Xbrane Biopharma AB
Figures in Million
consolidated Cash Flow Results
Change(SEK)
Change(%)
Profit Before Tax
-43.933
-66.677065096593
23.00
34.11%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-249.772
1.09598414347255
-250.00
-22889.75%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-250.691
-54.8095886201826
-196.00
-357.39%
Cash Flow from Investing Activities
-37.144
-44.3495396839013
7.00
16.25%
Cash Flow from Financing Activities
255.605
143.913544403639
112.00
77.61%
Net Cash Inflow / Outflow
-38.275
44.7544160995549
-82.00
-185.52%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-6.045
0
-6.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -87.46% vs 67.12% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-250.69
-133.73
-87.46%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
